Dianthus Therapeutics, Inc. /DE/ — Investor Relations & Filings
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases. The company engineers novel monoclonal antibodies with potentially best-in-class properties, focusing on proven mechanisms of action. Its lead candidate, claseprubart (DNTH103), is a potent and highly selective antibody targeting the active C1s complement protein. It is engineered with an extended half-life designed to allow for convenient, less frequent self-administered subcutaneous injections. The company's pipeline also includes DNTH212, a bifunctional inhibitor that targets Type 1 IFN suppression and B cell modulation. Dianthus aims to transform treatment for patients by developing therapies with the potential for improved clinical outcomes and greater convenience.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-04-09 | English | |
| DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-04-09 | English | |
| 4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer) | 2026-03-26 | English | |
| 8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-03-26 | English | |
| 4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer) | 2026-03-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 33935830 | ARS - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-04-09 | English | ||
| 33936285 | DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-04-09 | English | ||
| 33052761 | 4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer) | 2026-03-26 | English | ||
| 33048200 | 8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer) | 2026-03-26 | English | ||
| 32967973 | 4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer) | 2026-03-17 | English | ||
| 31319741 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31319894 | 4 Filing | 2026-02-04 | English | ||
| 31319869 | 4 Filing | 2026-02-04 | English | ||
| 31319787 | 4 Filing | 2026-02-04 | English | ||
| 31319783 | 4 Filing | 2026-02-04 | English | ||
| 31319755 | 4 Filing | 2026-02-04 | English | ||
| 32896686 | S-3 - DIANTHUS THERAPEUTICS, INC. /DE/ (0001690585) (Filer) | 2026-01-28 | English | ||
| 12995193 | 8-K | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 12995197 | 4 | 2025-12-06 | English | ||
| 12995194 | Regulatory Filings 2025 | 2025-12-04 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Dianthus Therapeutics, Inc. /DE/ via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31874/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31874 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31874 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31874 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31874}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Dianthus Therapeutics, Inc. /DE/ (id: 31874)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.